TABLE 3.
Dysregulation of TMPO-AS1 or other genes that interact with TMPO-AS1 in clinical specimens (PANTs: paired adjacent normal tissues, OS: overall survival, LNM: lymph node metastasis, BCR: biochemical recurrence).
| Tumor type | Samples | Expression of TMPO-AS1 or other genes (tumor vs Normal) | Cancer/TNM stage | Kaplan-meier analysis (impact of TMPO-AS1 dysregulation) | Univariate/Multivariate cox regression | Association of TMPO-AS1 expression with clinicopathologic features | Related pathways/targets | References |
|---|---|---|---|---|---|---|---|---|
| Nasopharyngeal carcinoma (NPC) | 45 NPC tissue samples and 22 normal nasopharynx tissues | Upregulated (which sponges miR320-a) | I-IV | - | - | Associated with metastasis and advanced clinical stage | miR-320a/SOX4 axis | Xing et al. (2021) |
| Bladder cancer (BC) | 40 fresh cancer tissues and PANTs | Upregulated (which sponges miR-98-5p) | T1-T4 | Poor OS | Independent prognostic factor | - | EBF1 | Luo et al. (2020) |
| 6 cancerous and PANTs | Upregulated | I-IV | Poor OS | - | Associated with recurrence of BC + advanced tumor stage | OTUB1/E2F1 | Zhang et al. (2021) | |
| Hepatocellular carcinoma (HCC) | 42 HCC samples and PANTs | Upregulated | I-IV | Poor OS | - | Associated with TNM stage and metastasis | miR-320a/SERBP1 axis | Wang et al. (2020) |
| 48 HCC samples and PANTs | Upregulated | I-IV | Poor OS | - | Associated with Tumor size, Lymphatic metastasis, TNM | miR-329-3p/FOXK1 axis | Guo and Wang, (2020) | |
| 53 HCC samples and PANTs | Upregulated | - | Poor OS | - | Associated with TNM stages, portal vein tumor thrombosis | miR-126-3p/LRP6/β-catenin axis | Huang et al. (2021) | |
| Osteosarcoma | 51 samples of cancer tissues and PANTs | Upregulated | - | - | - | - | miR-329/E2F1 axis | Liu et al. (2020b) |
| 56 cancer tissues and PANTs | Upregulated (which sponges miR-199a‐5p) | - | - | - | - | miR-199a‐5p/WNT7B axis | Cui and Zhao, (2020) | |
| Breast cancer | 22 cancer tissues and PANTs | Upregulated (which sponges miR-4731-5p) | I-IV | Poor OS | - | - | miR-4731-5p | Wang et al. (2021) |
| 40 Breast cancer tissues+ 15 healthy controls | Upregulated (which sponges miR-140-5p) | - | - | - | - | miR-140-5p | Zhu et al. (2021) | |
| 115 breast cancer tissues | Upregulation resulted in poor prognosis | I-III | Poor OS | Prognostic factor for OS and distant disease-free survival | Associated with stage, pathological T factor, histological grade and HER2 status | ESR1 | Mitobe et al. (2019) | |
| Laryngeal squamous cell carcinoma (LSCC) | 187 cancer tissues and PANTs | Upregulated | I-IV | Poor OS | Independent prognostic biomarker for LSCC patients | Associated with clinical stage, LNM | - | (Zhang et al., 19922020) |
| Lung Carcinoma (LC) | 50 cancer tissues and PANTs | Upregulated | - | Poor OS | - | - | miR-143-3p | Li et al. (2021) |
| Lung adenocarcinoma (LUAD) | 25 cancer tissues and PANTs + GEPIA | Upregulated | I-IV | Poor OS | - | Associated with TNM stage, LMN and high risk of mortality | miR-326/SOX12/E2F1 axis | Wei et al. (2020) |
| 6 cancer tissues and PANTs | Upregulated | - | Poor OS | - | - | miR-383-5p | Mu et al. (2020) | |
| Retinoblastoma | tissue samples from 33 children + normal retinal pigment epithelial tissue |
Upregulated | A-E (Based on tumor progression) | - | - | - | HIF-1α/miR-199a-5p | Peng et al. (2020) |
| Cholangiocarcinoma | 36 cancer tissues and PANTs | Upregulated | I-IV | - | - | - | let-7g-5p/HMGA1 | Chang and Yao, (2022) |
| Ovarian cancer | 86 cancer tissues and PANTs | Upregulated (promotes LCN2) | I-IV/G1-G3 (Fuhrman) | Poor OS | - | Associated with TNM stage, Fuhrman grade and tumor size | LCN2/E2F6 | Zhao et al. (2020a) |
| Non-small cell lung cancer | 30 cancer tissues and PANTs | Upregulated (which Sponges miR-204-3p) | - | Poor OS | - | - | miR-204-3p/ERBB2 axis | Yu et al. (2020) |
| 40 cancer tissues and PANTs | Upregulated | I-III | Poor OS | Lymph node metastasis is an independent prognostic factor | Associated with TNM stage and LMN | TMPO | Qin et al. (2019) | |
| Gastric cancer | 70 cancer tissues and PANTs | Upregulated (which Sponges miR-126-5p) | I-IV | Poor OS | - | Associated with TNM stage and LMN | miR-126-5p/PI3K/Akt/mTOR pathway/BRCC3 | Hu et al. (2021) |
| 105 cancer tissues and PANTs | Upregulated (which Sponges miR-140-5p) | I-IV | Poor OS | - | Associated with larger tumor size and advanced TNM stage | miR-140-5p/SOX4 axis | Sun and Han, (2020) | |
| Pancreatic carcinoma | 38 cancer tissues and PANTs | Upregulated | - | - | - | - | miR-383-5p/SOX11 axis | Xue et al. (2021) |
| Thyroid cancer | 40 cancer tissues and PANTs | Upregulated | - | - | - | - | miR-498 | Li et al. (2020b) |
| Gallbladder carcinoma (GBC) | 30 cancer tissues and PANTs | Upregulated | I-IV | Poor OS | Poor OS | - | miR-1179 /E2F2 axis |
Sui and Sui, (2021) |
| Colorectal cancer | 50 cancer tissues and PANTs | Upregulated | I-IV | - | - | Associated with LMN and distant metastasis | - | Mohammadrezakhani et al. (2020) |
| Prostate cancer | 54 cancer tissues and PANTs | Upregulated | pT2a-pT4 | Higher BCR | - | Associated with Gleason score, pathological stage, pathological stage and PSA level | AR | Huang et al. (2018) |
| Esophageal squamous cell carcinoma | 108 samples + TCGA dataset | Upregulated | I-IV | Poor OS | - | - | FUS/p300 | Luo et al. (2022) |